Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status

Better Therapeutics (BTTX) recently announced that its innovative Cognitive Behavioral Therapy (CBT) platform has received Breakthrough Device Designation from the FDA to treat people with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH.The breakthrough status is significant for the company as technologies achieving Breakthrough Device Designation show promise for outperforming the existing standard of care for patients with severe or life-threatening diseases.Price Performan ...